– Weiterer Beitrag zum Wachstum unserer Kunden durch Stärkung der Umsetzungskompetenzen –
TOKIO, Feb. 15, 2026 (GLOBE NEWSWIRE) -- Die Dentsu Group Inc. (Tokio: 4324; [...] Read more »
Dentsu annonce une nouvelle structure de direction mondiale
– Renforcer les capacités d’exécution pour contribuer davantage à la croissance des clients –
TOKYO, 15 févr. 2026 (GLOBE NEWSWIRE) -- [...] Read more »
Al Tamimi & Company تعيّن Dr. Bashayer Al-Majed في منصب المستشار القانوني الأول
مدينة الكويت، الكويت, Feb. 13, 2026 (GLOBE NEWSWIRE) -- [...] Read more »
Al Tamimi & Company Appoints Dr. Bashayer Al-Majed as Senior Counsel
KUWAIT CITY, Kuwait, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Al Tamimi & Company, the leading law firm in the Middle East and North Africa, has announced the appointment of Dr. Bashayer Al-Majed as Senior Counsel, reinforcing the [...] Read more »
Dentsu Announces New Global Management Structure
– Further Contributing to Client Growth by Strengthening Execution Capabilities –
TOKYO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Dentsu Group Inc. (Tokyo: 4324; ISIN: [...] Read more »
Helus Pharma nomme Michael Cola au poste de directeur général pour piloter la prochaine phase de développement et d’exécution
- Ancien président de la division pharmaceutique spécialisée de Shire PLC (« Shire »), il cumule plus de 30 ans d’expérience dans les domaines des [...] Read more »
Helus Pharma ernennt Michael Cola zum Chief Executive Officer für die Leitung der nächsten Skalierungs- und Durchführungsphase
- Er ist ehemaliger President des Spezialpharmazeutika-Geschäftsbereichs von Shire PLC („Shire“) mit über 30 Jahren Erfahrung auf dem Gebiet von Neurowissenschaften, seltenen [...] Read more »
Helus Pharma Nomeia Michael Cola como Diretor Executivo para Liderar a Próxima Fase de Escala e Execução
- Ex-presidente da empresa farmacêutica especializada da Shire PLC ("Shire"), com mais de 30 anos de experiência em neurociência, doenças raras e produtos [...] Read more »
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
- Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at [...] Read more »
Angelini Pharma Announces Appointment of Sergio Marullo di Condojanni as New CEO
ROME, Jan. 21, 2026 (GLOBE NEWSWIRE) — Angelini Pharma, part of the multinational privately owned industrial group Angelini Industries, today announced the appointment of Sergio Marullo di Condojanni as Chief [...] Read more »